574 related articles for article (PubMed ID: 17976523)
1. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
2. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
3. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
Snyder DS; Palmer J; Stein AS; Pullarkat V; Sahebi F; Cohen S; Vora N; Gaal K; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1161-8. PubMed ID: 17085309
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Kröger N; Zabelina T; Schieder H; Panse J; Ayuk F; Stute N; Fehse N; Waschke O; Fehse B; Kvasnicka HM; Thiele J; Zander A
Br J Haematol; 2005 Mar; 128(5):690-7. PubMed ID: 15725091
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
8. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Nagi W; Lim ZY; Krishnamurthy P; Potter V; Tindell V; Reiff-Zall L; Abdullah A; Lea N; Kenyon M; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2011 Aug; 35(8):998-1000. PubMed ID: 21704371
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
[TBL] [Abstract][Full Text] [Related]
14. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
Molina A; Zain J; Arber DA; Angelopolou M; O'Donnell M; Murata-Collins J; Forman SJ; Nademanee A
J Clin Oncol; 2005 Sep; 23(25):6163-71. PubMed ID: 16135483
[TBL] [Abstract][Full Text] [Related]
15. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
19. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
TAHARA K; YOKOHAMA A; HANDA H; SAITOH T; UCHIUMI H; SEKIGAMI T; TOYAMA K; MAWATARI M; OSAKI Y; MATSUSHIMA T; KARASAWA M; MURAKAMI H; TSUKAMOTO N; NOJIMA Y
Rinsho Ketsueki; 2009 Nov; 50(11):1630-4. PubMed ID: 20009439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
